Home>Articles>Hugin pushes back on claims of greed

Hugin pushes back on claims of greed

New TV ad seeks to show his compassionate side

By David Wildstein, July 13 2018 11:32 am

Republican U.S. Senate candidate Bob Hugin has a new ad that rebuts claims made by a super PAC that Hugin has profited by overcharging for a cancer-fighting drug manufactured by the pharmaceutical company he ran.

The ad, titled “Ryan” features the father of a young cancer patient,   Kirby Davidson, talking about how Hugin and his company, Celgene, stepped in to help his son.

“Bob Hugin spent the last two decades working to improve the quality and extend the lives of people diagnosed with terminal disease,” said his campaign manager, Stacy Schuster.

Schuster accused the Menendez campaign of lying about Hugin’s record at Celgene.

“His campaign chairman called Bob Hugin a ‘bloodsucker’ and even went so far as to infer that he killed people during his time at Celgene,” Schuster said. “These disgusting attacks are fitting of a desperate politician like Bob Menendez and clear evidence that he’s scared.”

The super PC, Patients for Affordable Drugs Action, is spending an estimated $1.5 million on a TV ad slamming Hugin.

In the ad, cancer patient Pam Holt says the Revlimid keeps her alive and that Celgene charges over $600 for a drug that costs them less than $1 to make.

“Now he wants to be your Senator,” Holt says.  “But I’ll always know him as the guy who made a killing – off cancer patients like me.”

Schuster’s comments caught the attention of the Menendez campaign.

“Bob Hugin is funding his campaign with blood money he pocketed from ripping off cancer patients,” said Michael Soliman, Menendez’s campaign chairman.  “The facts are the facts.”

Editor’s note: comment from the Menendez campaign was added.)

Spread the news:
RELATED ARTICLES
Filter by
Post Page
Highlight Bergen Legislature Articles Mercer Congress
Sort by

Hugin to appear at GOP fundraiser in 38th district

Ex-U.S. Senate candidate to help Kazimir, DiPiazza raise money
July 2, 2019 2:31 pm

18

Hugin is back

March 17, 2019 1:03 am

18

Bob Hugin named to drug maker board seat

Ex-U.S. Senate candidate spent $36 million to win New Jersey seat
February 19, 2019 11:59 am

18

One thought on “Hugin pushes back on claims of greed

  1. What Celgene should be concerned about, even more than the class action lawsuits on keeping generic similar drugs off the market is the toxicity of revlimid. The drug caused respiratory failure, peripheral neurology, heart failure, blood clots, and cellulitis (a potentially fatal skin infection in my husband). He would have lived longer with fewer problems without any treatment for his multiple myeloma After his death we learned that revlimid was not approved as the first treatment for asymtomatic myeloma because it was so toxic. Celegene was being suited for paying doctors to prescribe the drug off label in an attempt to get it approved as a first treatment.

Leave a Reply

Your email address will not be published. Required fields are marked *